This message was sent to ##Email##
|
| November 27, 2019 |
| |  | | |
|
|
|
| |
CNN
Over the past decade, the rate of new lung cancer cases diagnosed in the U.S. has dropped 19% and the five-year survival rate has climbed 26%, according to a new report.
Yet lung cancer remains the leading cause of cancer death nationwide — and your chances of surviving lung cancer can vary drastically depending on where you live.
READ MORE
 |
|
EcoVue® was designed with patient safety in mind, our non-refillable and single use products will forever CHANGE YOUR VUE of ultrasound gel.
www.EcoVue.com
|
|
ASCT
ASCT has extended the deadline for speaker submissions for our upcoming 2020 Annual Conference, to be held in Palm Springs, California May 1-3. If you have an idea for a lecture or workshop we would love to hear from you. Click here to download the submission form. Please return the form to info@asct.com by December 2nd. We look forward to hearing from you!
 |
|
The F-50 Non-Gyn Slide Processor has a liquid-based cytology system that features more cells per slide, and doesn’t need duplicate preps. The dual filtration disposable filters remove non-diagnostic material to optimize cell presentation. Cells of interest are transferred to the slide in a homogenous thin-layer cell deposit. Throughput: 50 samples/hr.
|
|
| Date |
Event |
Location |
More information |
November 2019
|
IHC Valication
— Lynnette Savaloja Pineault, MBA, SCT(ASCP)
|
Your PC |
Details |
December 11, 2019
|
EBUS ROSE with an Emphasis on Telecytology and Diagnoses other than Lung Cancer —
Michael Thrall, MD
|
Your PC |
Details |
Available for 6 months after subscribing |
Quality Assessment Center (QAC) Cell Blocks Basics Workbench
|
Your PC |
Details |
Available for 6 months after subscribing |
Quality Assessment Center (QAC)
Document Control for Cytopathology Workbench
|
Your PC |
Details |
Available for 6 months after subscribing |
Quality Assessment Center (QAC)
The LEAN Cytopathology Laboratory Workbench
|
Your PC |
Details |
DocWire
Imprisoned women are at higher risk of cervical cancer and HPV infection than the general population, according to a study published in the Journal of Epidemiology & Community Health.
Researchers conducted a systematic review of published and unpublished data on the prevalence of any HPV infection, cervical intraepithelial neoplasia (CIN), and cervical cancer in imprisoned women.
READ MORE
HealthDay via Medical Xpress
The safety of the 9-valent human papillomavirus vaccine (9vHPV) has again been confirmed, according to two studies published online in Pediatrics. Tom T. Shimabukuro, MD, MPH, from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues searched the Vaccine Adverse Event Reporting System (VAERS) for reports of adverse events (AEs) after 9vHPV from December 2014 through December 2017. The researchers found that the VAERS received 7,244 reports after 9vHPV; 97.4% were nonserious.
READ MORE
University of Texas Health Science Center at Houston
Rates of new anal cancer diagnoses and deaths related to human papillomavirus (HPV), the most common sexually transmitted infection, have increased dramatically over the last 15 years, according to researchers at The University of Texas Health Science Center at Houston (UTHealth). The study was the first to compare and categorize contemporary national trends in incidence of squamous cell carcinoma of the anus, a type of anal cancer caused by HPV, by stage at diagnosis, year of birth, and mortality. It found that anal cancer diagnoses, particularly advanced stage disease, and anal cancer mortality rates had more than doubled for people in their 50s and 60s.
READ MORE
FDA
The U.S. Food and Drug Administration granted accelerated approval to Brukinsa capsules for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy. "Mantle cell lymphoma usually responds well to initial treatment, but eventually returns or stops responding, and the cancer cells continue to grow," said Dr. Richard Pazdur, director of the FDA’s Oncology Center of Excellence. "Clinical trials showed that 84% of patients saw tumor shrinkage with this therapy."
READ MORE
|
|
|
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
